Loading...
Please wait, while we are loading the content...
Similar Documents
Comparison of everolimus-eluting and sirolimus-eluting coronary stents: 1-year outcomes from the Randomized Evaluation of Sirolimus-eluting Versus Everolimus-eluting stent Trial (RESET).
| Content Provider | Semantic Scholar |
|---|---|
| Author | Kimura, Takeshi Morimoto, Takeshi Natsuaki, Masahiro Shiomi, Hiroki Igarashi, Keiichi Kadota, Kazushige Tanabe, Kengo Morino, Yoshihiro Akasaka, Takashi Takatsu, Yoshiki Nishikawa, Hideo Yamamoto, Yoshito Nakagawa, Yoshihisa Hayashi, Yasuhiko Iwabuchi, Masashi Umeda, Hisashi Kawai, Kazuya Okada, Hisayuki Kimura, Kazuo Simonton, Charles A. Kozuma, Ken |
| Copyright Year | 2012 |
| Abstract | BACKGROUND Several recent randomized trials comparing everolimus-eluting stent (EES) and sirolimus-eluting stent (SES) reported similar outcomes. However, only 1 trial was powered for a clinical end point, and no trial was powered for evaluating target-lesion revascularization. METHODS AND RESULTS Randomized Evaluation of Sirolimus-eluting versus Everolimus-eluting stent Trial is a prospective multicenter randomized open-label trial comparing EES with SES in Japan. The trial was powered for evaluating noninferiority of EES relative to SES in terms of target-lesion revascularization. From February and July 2010, 3197 patients were randomly assigned to receive either EES (1597 patients) or SES (1600 patients). At 1 year, the primary efficacy end point of target-lesion revascularization occurred in 65 patients (4.3%) in the EES group and in 76 patients (5.0%) in the SES group, demonstrating noninferiority of EES to SES (P(noninferiority)<0.0001, and P(superiority)=0.34). Cumulative incidence of definite stent thrombosis was low and similar between the 2 groups (0.32% versus 0.38%, P=0.77). An angiographic substudy enrolling 571 patients (EES, 285 patients and SES, 286 patients) demonstrated noninferiority of EES relative to SES regarding the primary angiographic end point of in-segment late loss (0.06±0.37 mm versus 0.02±0.46 mm, P(noninferiority)<0.0001, and P(superiority)=0.24) at 278±63 days after index stent implantation. CONCLUSIONS One-year clinical and angiographic outcome after EES implantation was noninferior to and not different from that after SES implantation in a stable coronary artery disease population with relatively less complex coronary anatomy. One-year clinical outcome after both EES and SES use was excellent with a low rate of target-lesion revascularization and a very low rate of stent thrombosis. CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov. Unique identifier: NCT01035450. |
| File Format | PDF HTM / HTML |
| DOI | 10.1161/CIRCULATIONAHA.112.104059 |
| PubMed reference number | 22824435 |
| Journal | Medline |
| Volume Number | 126 |
| Issue Number | 10 |
| Alternate Webpage(s) | http://circ.ahajournals.org/content/circulationaha/early/2012/07/23/CIRCULATIONAHA.112.104059.full.pdf |
| Alternate Webpage(s) | http://circ.ahajournals.org/content/circulationaha/126/10/1225.full.pdf?download=true |
| Alternate Webpage(s) | http://circ.ahajournals.org/content/circulationaha/early/2012/07/23/CIRCULATIONAHA.112.104059.full.pdf?download=true |
| Journal | Circulation |
| Language | English |
| Access Restriction | Open |
| Content Type | Text |
| Resource Type | Article |
